$ETNB
89bio, Inc.

2021 Q4 Form 10-K Financial Statement

#000156459022011706 Filed on March 24, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.262M $19.41M $3.780M
YoY Change 39.21% 47.52% 56.2%
% of Gross Profit
Research & Development $20.98M $70.33M $8.770M
YoY Change 139.21% 94.29% 21.97%
% of Gross Profit
Depreciation & Amortization $21.00K $79.00K $10.00K
YoY Change 110.0% 31.67% 0.0%
% of Gross Profit
Operating Expenses $26.24M $89.74M $12.55M
YoY Change 109.09% 81.83% 30.59%
Operating Profit -$89.74M
YoY Change 81.83%
Interest Expense $0.00 -$400.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$194.0K -$526.0K -$120.0K
YoY Change 61.67% 159.11% -98.74%
Pretax Income -$26.44M -$90.27M -$12.66M
YoY Change 108.81% 82.15% -33.89%
Income Tax -$147.0K -$147.0K -$80.00K
% Of Pretax Income
Net Earnings -$26.29M -$90.12M -$12.58M
YoY Change 108.97% 82.07% -34.76%
Net Earnings / Revenue
Basic Earnings Per Share -$4.48
Diluted Earnings Per Share -$1.297M -$4.484M -$631.5K
COMMON SHARES
Basic Shares Outstanding 20.10M
Diluted Shares Outstanding 20.10M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $150.7M $150.7M $204.6M
YoY Change -26.33% -26.33% 119.29%
Cash & Equivalents $52.43M $52.43M $98.18M
Short-Term Investments $98.29M $98.29M $106.4M
Other Short-Term Assets $11.26M $11.26M $5.500M
YoY Change 104.76% 104.76% 175.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $162.0M $162.0M $210.2M
YoY Change -22.94% -22.94% 120.51%
LONG-TERM ASSETS
Property, Plant & Equipment $150.0K $150.0K $166.0K
YoY Change -9.64% -25.0% 7.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $290.0K $290.0K $706.0K
YoY Change -58.92% -58.57% 880.56%
Total Long-Term Assets $440.0K $440.0K $872.0K
YoY Change -49.54% -51.11% 284.14%
TOTAL ASSETS
Total Short-Term Assets $162.0M $162.0M $210.2M
Total Long-Term Assets $440.0K $440.0K $872.0K
Total Assets $162.4M $162.4M $211.1M
YoY Change -23.05% -23.06% 120.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.843M $6.843M $2.065M
YoY Change 231.38% 225.86% 108.8%
Accrued Expenses $10.19M $10.19M $6.048M
YoY Change 68.55% 69.9% 30.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.500M $2.500M
YoY Change
Total Short-Term Liabilities $19.54M $19.54M $8.113M
YoY Change 140.81% 141.2% 44.88%
LONG-TERM LIABILITIES
Long-Term Debt $16.90M $16.90M $0.00
YoY Change
Other Long-Term Liabilities $30.00K $30.00K
YoY Change
Total Long-Term Liabilities $16.90M $16.93M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $19.54M $19.54M $8.113M
Total Long-Term Liabilities $16.90M $16.93M $0.00
Total Liabilities $36.47M $36.47M $8.113M
YoY Change 349.46% 350.19% 44.88%
SHAREHOLDERS EQUITY
Retained Earnings -$213.2M -$123.1M
YoY Change 73.21% 67.26%
Common Stock $339.2M $326.1M
YoY Change 4.04% 99.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $126.0M $126.0M $203.0M
YoY Change
Total Liabilities & Shareholders Equity $162.4M $162.4M $211.1M
YoY Change -23.05% -23.06% 120.9%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$26.29M -$90.12M -$12.58M
YoY Change 108.97% 82.07% -34.76%
Depreciation, Depletion And Amortization $21.00K $79.00K $10.00K
YoY Change 110.0% 31.67% 0.0%
Cash From Operating Activities -$28.24M -$76.78M -$14.02M
YoY Change 101.43% 66.03% 25.97%
INVESTING ACTIVITIES
Capital Expenditures -$27.00K $63.00K -$10.00K
YoY Change 170.0% -50.0% -90.91%
Acquisitions
YoY Change
Other Investing Activities $19.11M $7.222M -$29.03M
YoY Change -165.84% -106.77%
Cash From Investing Activities $19.09M $7.159M -$29.03M
YoY Change -165.75% -106.7% 26290.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.89M 23.87M -320.0K
YoY Change -6940.94% -84.88% -100.36%
NET CHANGE
Cash From Operating Activities -28.24M -76.78M -14.02M
Cash From Investing Activities 19.09M 7.159M -29.03M
Cash From Financing Activities 21.89M 23.87M -320.0K
Net Change In Cash 12.74M -45.75M -43.37M
YoY Change -129.37% -1043.71% -156.23%
FREE CASH FLOW
Cash From Operating Activities -$28.24M -$76.78M -$14.02M
Capital Expenditures -$27.00K $63.00K -$10.00K
Free Cash Flow -$28.21M -$76.84M -$14.01M
YoY Change 101.38% 65.72% 27.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.869
CY2021 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-06-30
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.864
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.007
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.002
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.919
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.976
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.013
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.015
CY2021 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
ETNB
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
706000
CY2021Q4 us-gaap Assets
Assets
162422000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19537000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8113000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16898000
CY2021Q4 etnb Other Non Current Liability
OtherNonCurrentLiability
30000
CY2021Q4 us-gaap Liabilities
Liabilities
36465000
CY2021 dei Auditor Firm
AuditorFirmId
185
CY2021 dei Auditor Name
AuditorName
KPMG LLP
CY2021 dei Auditor Location
AuditorLocation
San Francisco, California, USA
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52432000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98183000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
25000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
25000
CY2021Q4 etnb Short Term Available For Sale Securities Current
ShortTermAvailableForSaleSecuritiesCurrent
98288000
CY2020Q4 etnb Short Term Available For Sale Securities Current
ShortTermAvailableForSaleSecuritiesCurrent
106446000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11237000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5548000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
161982000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
210202000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
150000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
166000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
290000
CY2020Q4 us-gaap Assets
Assets
211074000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6843000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2065000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10194000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6048000
CY2021Q4 etnb Term Loan Current
TermLoanCurrent
2500000
CY2020Q4 us-gaap Liabilities
Liabilities
8113000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20317204
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20317204
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19931660
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19931660
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
339218000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
326046000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-64000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-213217000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-71000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
8000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
17000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-18000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-10000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-268000
CY2021 etnb Amortization Of Debt Issuance Costs And Accretion Of Final Payment Fee
AmortizationOfDebtIssuanceCostsAndAccretionOfFinalPaymentFee
-617000
CY2020 etnb Amortization Of Debt Issuance Costs And Accretion Of Final Payment Fee
AmortizationOfDebtIssuanceCostsAndAccretionOfFinalPaymentFee
-230000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123095000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
125957000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
202961000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
162422000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
211074000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70330000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36199000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19413000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13156000
CY2021 us-gaap Operating Expenses
OperatingExpenses
89743000
CY2020 us-gaap Operating Expenses
OperatingExpenses
49355000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-89743000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-49355000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-526000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-203000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-90269000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49558000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-147000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-59000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-90122000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.48
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.08
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20098340
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16087785
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
271000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
134000
CY2020 etnb Issuance Of Common Stock Warrant In Connection With Term Loan Facility
IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility
634000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-49499000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-10000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
202961000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
487000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
144000
CY2021 etnb Issuance Of Common Stock Warrant In Connection With Term Loan Facility
IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility
574000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-90122000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-54000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
125957000
CY2021 us-gaap Profit Loss
ProfitLoss
-90122000
CY2020 us-gaap Profit Loss
ProfitLoss
-49499000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
8678000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3807000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-865000
CY2021 us-gaap Depreciation
Depreciation
79000
CY2020 us-gaap Depreciation
Depreciation
60000
CY2021 etnb Deferred Tax Assets
DeferredTaxAssets
150000
CY2020 etnb Deferred Tax Assets
DeferredTaxAssets
69000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5672000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3600000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4778000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1131000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4146000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1428000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-76781000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46244000
CY2021 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
148422000
CY2020 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
12189000
CY2021 etnb Payment For Purchase Of Available For Sale Securities
PaymentForPurchaseOfAvailableForSaleSecurities
141200000
CY2020 etnb Payment For Purchase Of Available For Sale Securities
PaymentForPurchaseOfAvailableForSaleSecurities
118895000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
63000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
126000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7159000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-106832000
CY2021 us-gaap Proceeds From Issuance Of Other Long Term Debt
ProceedsFromIssuanceOfOtherLongTermDebt
19951000
CY2021 etnb Proceeds From Issuance Public Offering
ProceedsFromIssuancePublicOffering
3289000
CY2020 etnb Proceeds From Issuance Public Offering
ProceedsFromIssuancePublicOffering
157680000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
487000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
271000
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
161000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23871000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
157924000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-45751000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4848000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98208000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93360000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52457000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98208000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52432000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98183000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
25000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
25000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52457000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98208000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
16000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
142000
CY2021 etnb Issuance Of Common Stock Warrant In Connection With Term Loan Facility
IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility
574000
CY2020 etnb Issuance Of Common Stock Warrant In Connection With Term Loan Facility
IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility
634000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
150700000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include but are not limited to accrued research and development expenses and the fair value of stock options. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</p>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#231F20;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial<span style="letter-spacing:0.05pt;"> </span>instruments<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>potentially<span style="letter-spacing:0.1pt;"> </span>subject<span style="letter-spacing:0.05pt;"> </span>the Company to a concentration<span style="letter-spacing:0.1pt;"> </span>of credit<span style="letter-spacing:0.05pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>consist primarily<span style="letter-spacing:0.1pt;"> </span>of cash and cash equivalents and short-term available-for-sale securities.<span style="letter-spacing:0.1pt;"> </span>Bank<span style="letter-spacing:-0.05pt;"> </span>deposits<span style="letter-spacing:0.05pt;"> </span>are held by accredited<span style="letter-spacing:0.1pt;"> </span>financial<span style="letter-spacing:0.1pt;"> </span>institutions<span style="letter-spacing:0.1pt;"> </span>and these deposits<span style="letter-spacing:0.05pt;"> </span>may at times<span style="letter-spacing:0.05pt;"> </span>be in excess<span style="letter-spacing:0.05pt;"> </span>of insured<span style="letter-spacing:0.05pt;"> </span>limits. The Company limits<span style="letter-spacing:0.1pt;"> </span>its<span style="letter-spacing:0.05pt;"> </span>credit<span style="letter-spacing:0.05pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>associated<span style="letter-spacing:0.1pt;"> </span>with cash and cash equivalents<span style="letter-spacing:0.1pt;"> </span>by placing<span style="letter-spacing:0.05pt;"> </span>them<span style="letter-spacing:0.05pt;"> </span>with financial<span style="letter-spacing:0.1pt;"> </span>institutions<span style="letter-spacing:0.1pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>it believes<span style="letter-spacing:0.05pt;"> </span>are of high quality.<span style="letter-spacing:0.05pt;"> </span>The Company has not experienced<span style="letter-spacing:0.05pt;"> </span>any losses<span style="letter-spacing:0.05pt;"> </span>on its<span style="letter-spacing:0.05pt;"> </span>deposits<span style="letter-spacing:0.05pt;"> </span>of cash or cash equivalents. The Company <span style="color:#000000;">limits amounts invested in available-for-sale securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></p>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 etnb Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
7895000
CY2020Q4 etnb Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
2534000
CY2021Q4 us-gaap Prepaid Taxes
PrepaidTaxes
836000
CY2020Q4 us-gaap Prepaid Taxes
PrepaidTaxes
481000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2506000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2533000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11237000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5548000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
120726000
CY2021Q4 etnb Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
5277000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
126003000
CY2021Q4 etnb Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
6195000
CY2020Q4 etnb Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2884000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3168000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2552000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
495000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
453000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6048000
CY2018Q2 us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
The Company amended the lease term to expire in April 2022, with an option to renew for an additional 12 months.
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
336000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
159000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10194000
CY2018Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
CY2018Q2 etnb Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
4200
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
212000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
219000
CY2021 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
290000
CY2020 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
273000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0075
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.923
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2021 etnb Percentage Of Fee On Loan
PercentageOfFeeOnLoan
0.05
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Rolling Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextRollingTwelveMonths
2500000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo
10000000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Rolling Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree
7500000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
602000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
19398000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2500000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16898000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
69000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-147000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-59000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
6529000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
5392000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1969000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
610000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-11000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-2000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-1000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-3000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-10000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
150000
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
69000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
150000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
220000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
635000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
191000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
48000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42265000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22005000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42046000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21936000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
219000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
69000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42000000.0
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21900000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
20100000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
11900000
CY2020 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
Federal net operating losses generated after 2017 can be carried forward indefinitely but utilization will be limited to 80% of taxable income in the period that net operating losses are being utilized.
CY2020Q4 etnb Taxable Income Utilization Percentage
TaxableIncomeUtilizationPercentage
0.80
CY2021Q4 etnb Deferred Tax Assets Tax Credit Carryforwards Research Federal
DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal
2100000
CY2020Q4 etnb Deferred Tax Assets Tax Credit Carryforwards Research Federal
DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal
600000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1100000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
700000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-90269000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49558000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
18757000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
8285000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-20111000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-11914000
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-19000
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
1671000
CY2021 etnb Income Tax Reconciliation Change In Effective Tax Rate Due To Reorganization
IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization
-2000
CY2020 etnb Income Tax Reconciliation Change In Effective Tax Rate Due To Reorganization
IncomeTaxReconciliationChangeInEffectiveTaxRateDueToReorganization
647000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
1331000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
815000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
191000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
555000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-147000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-59000
CY2021 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
500000
CY2020 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
300000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2571985
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1898395

Files In Submission

Name View Source Status
0001564590-22-011706-index-headers.html Edgar Link pending
0001564590-22-011706-index.html Edgar Link pending
0001564590-22-011706.txt Edgar Link pending
0001564590-22-011706-xbrl.zip Edgar Link pending
etnb-10k_20211231.htm Edgar Link pending
etnb-10k_20211231_htm.xml Edgar Link completed
etnb-20211231.xsd Edgar Link pending
etnb-20211231_cal.xml Edgar Link unprocessable
etnb-20211231_def.xml Edgar Link unprocessable
etnb-20211231_lab.xml Edgar Link unprocessable
etnb-20211231_pre.xml Edgar Link unprocessable
etnb-ex231_7.htm Edgar Link pending
etnb-ex311_9.htm Edgar Link pending
etnb-ex312_6.htm Edgar Link pending
etnb-ex321_10.htm Edgar Link pending
etnb-ex43_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gb2k1ptlkg5v000001.jpg Edgar Link pending
gb2k1ptlkg5v000002.jpg Edgar Link pending
gb2k1ptlkg5v000003.jpg Edgar Link pending
gb2k1ptlkg5v000004.jpg Edgar Link pending
gb2k1ptlkg5v000005.jpg Edgar Link pending
gb2k1ptlkg5v000006.jpg Edgar Link pending
gb2k1ptlkg5v000007.jpg Edgar Link pending
gb2k1ptlkg5v000008.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending